Tenpoint Therapeutics™ is pioneering a new treatment for presbyopia, BRIMOCHOL™ PF, with a PDUFA date from US FDA of January 28, 2026. The company also has a R&D pipeline of novel therapies for other unmet needs in ophthalmology.
ARTBIO
ARTBIO is a clinical-stage radiopharmaceutical company redefining cancer care by creating a new class of alpha radioligand therapies (ARTs). ARTBIO’s approach uses the optimal alpha-emitting isotope (Pb212) with tumor-specific targets to create unique radioligand therapeutics. The company’s AlphaDirectTM technology, a first-of-its-kind Pb212 isolation method, enables a distributed manufacturing approach for the reliable production and delivery of ARTs.
Albert Invent
Albert Invent is an end-to-end R&D platform for chemists and materials scientists, combining ELN, LIMS, inventory, and regulatory tools in one system. Powered by its AI engine, Breakthrough™, trained on over 15 million molecular structures, Albert enables predictive formulation, inverse design, and faster innovation cycles for the worlds largest chemical companies.
Cadence Neuroscience
Cadence Neuroscience is a medical device company developing new therapies for the treatment of epilepsy and other neurological disorders. The company’s core technology was developed at Mayo Clinic and is under clinical evaluation. Founded in 2017 and headquartered in Redmond, Washington, Cadence is led by seasoned executives with extensive backgrounds in neural implant product development and clinical studies.
Adcentrx Therapeutics
Adcentrx is a biotechnology company focused on accelerating breakthroughs in protein conjugate therapeutic development for cancer and other life-threatening diseases. By combining the targeting precision of biologics and the disease-fighting power of small molecule payloads, Adcentrx strives to develop next-generation targeted therapies for improving patient treatment options.
Aera Therapeutics
Aera’s mission is to unlock the potential of genetic medicines by tackling the greatest unmet need in the field today – delivery. Aera has two proprietary delivery platforms – lipid nanoparticles (LNPs) and protein nanoparticles (PNPs) – that are being developed to enable next-generation genetic medicines across a range of therapeutic modalities and disease areas. These platforms have the potential to overcome the limitations of today’s delivery technologies and expand the application of genetic medicines.
Bicara Therapeutics
Bicara Therapeutics is a clinical-stage biotechnology company developing first-in-class biologics engineered to bring together the precision of targeted therapy and the power of tumor modulators. The company’s bifunctional antibodies are designed to deliver an immunomodulatory payload directly to the tumor microenvironment to ramp up immune cell activity, potentially offering long-lasting efficacy.
TandemAI
TandemAI is an advanced technology company dedicated to reinventing drug discovery infrastructure. The company integrates proprietary AI-driven and physics-based high-performance computation with its efficient, large-scale in-house wet lab operations to deliver a turnkey drug discovery solution.
Curie.Bio
Curie.Bio is a founder-focused seed-stage venture firm combined with an industry-grade therapeutics accelerator focused on one thing: helping entrepreneurial founders launch viable therapeutics companies. Curie.Bio does this by giving founders access to a team of the world’s best drug hunters and drug makers, seed capital, and best-of-breed services—everything a founder needs to get from concept to a compelling quality dataset that enables an awesome Series A financing. In a nutshell, we want founders in control of their own company and focused on their area of expertise and creativity, while we help make the rest happen smoothly.
Canoe Intelligence
Canoe’s mission is to unlock efficiencies in alternative investment processes by introducing purpose-built automation into the workflows of institutional investors, asset servicers, capital allocators and wealth managers.